We are live on
!
Find out more
AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.94B
1-Year Est. Return
374.45%
This Fund
S&P 500
This Quarter
Est. Return
+15.94%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$732M
AUM Growth
-$316M
(-30%)
Cap. Flow
-$376M
Cap. Flow
% of AUM
-51.38%
Top 10 Holdings %
Top 10 Hldgs %
46.9%
Holding
119
New
21
Increased
21
Reduced
25
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$26M |
| 2 |
Insmed
INSM
|
+$25.6M |
| 3 |
Trevi Therapeutics
TRVI
|
+$7.99M |
| 4 |
Enliven Therapeutics
ELVN
|
+$7.57M |
| 5 |
VTYX
Ventyx Biosciences
VTYX
|
+$7.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$17.5M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$16.8M |
| 3 |
MRUS
Merus
MRUS
|
+$11.8M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$8.19M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$7.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.76% |
| 2 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Geron
GERN
$930M
| $2.12M | 0.29% |
1,500,000
| – | – |
|
|
THRD
52
DELISTED
Third Harmonic Bio
THRD
| $2.01M | 0.27% |
370,000
| – | – |
|
53
Cullinan Oncology
CGEM
$1.06B
| $1.99M | 0.27% |
263,817
| – | – |
|
54
NewAmsterdam Pharma Warrant
NAMSW
$89.1M
| $1.96M | 0.27% |
245,000
+3,043
| +1% | +$25.3K |
|
55
uniQure
QURE
$2.71B
| $1.88M | 0.26% |
135,000
-265,000
| -66% | -$3.56M |
|
|
CLYM
56
Climb Bio
CLYM
$731M
| $1.86M | 0.25% |
1,500,000
| – | – |
|
57
PUT
Capricor Therapeutics
CAPR
$1.15B
| $1.74M | 0.24% |
+175,000
| New | +$1.85M |
|
|
AVR
58
Anteris Technologies
AVR
$797M
| $1.61M | 0.22% |
425,000
+35,000
| +9% | +$142K |
|
|
ATXS
59
DELISTED
Astria Therapeutics
ATXS
| $1.61M | 0.22% |
+300,000
| New | +$1.45M |
|
60
CALL
Novavax
NVAX
$1.29B
| $1.57M | 0.22% |
+250,000
| New | +$1.66M |
|
|
61
CALL
uniQure
QURE
$2.71B
| $1.39M | 0.19% |
+100,000
| New | +$1.35M |
|
62
Nkarta
NKTX
$165M
| $1.33M | 0.18% |
800,000
| – | – |
|
63
Mirum Pharmaceuticals
MIRM
$6.97B
| $1.26M | 0.17% |
24,692
-25,000
| -50% | -$1.11M |
|
64
Savara
SVRA
$1.18B
| $1.14M | 0.16% |
+500,000
| New | +$1.36M |
|
65
Olema Pharmaceuticals
OLMA
$1.03B
| $1.06M | 0.15% |
250,000
-75,000
| -23% | -$334K |
|
66
NextCure
NXTC
$17M
| $1.06M | 0.14% |
191,883
| – | – |
|
67
PUT
Omeros
OMER
$744M
| $942K | 0.13% |
+314,000
| New | +$1.56M |
|
|
OKUR
68
OnKure Therapeutics
OKUR
$170M
| $832K | 0.11% |
347,990
-46,169
| -12% | -$121K |
|
69
PUT
INmune Bio
INMB
$45.7M
| $818K | 0.11% |
+354,000
| New | +$2.6M |
|
70
CALL
Altimmune
ALT
$552M
| $774K | 0.11% |
+200,000
| New | +$1.08M |
|
|
ABVX
71
Abivax
ABVX
$11.4B
| $765K | 0.1% |
100,000
-100,000
| -50% | -$652K |
|
72
CALL
Karyopharm Therapeutics
KPTI
$161M
| $679K | 0.09% |
+157,500
| New | +$773K |
|
|
JBIO
73
Jade Biosciences
JBIO
$1.19B
| $653K | 0.09% |
65,317
+42,460
| +186% | +$1.45M |
|
74
Sutro Biopharma
STRO
$391M
| $537K | 0.07% |
75,272
| – | – |
|
75
PUT
Galectin Therapeutics
GALT
$227M
| $528K | 0.07% |
250,000
-1,586,200
| -86% | -$2.37M |
|
Similar funds
FM
1SB
HCL
OCM
MWA
HC
FFH
BC
Affinity Asset Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Affinity Asset Advisors held 119 positions worth $732M, down 30% from $1.05B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Affinity Asset Advisors withdrew a net $376M in Q2 2025, closing 28 positions and reducing 25 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $16.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 55% a quarter earlier, followed by Financials.
Against the trend, Affinity Asset Advisors opened a new position in Blueprint Medicines worth $32M.
- Affinity Asset Advisors's largest Q2 2025 buy was Blueprint Medicines: 250,000 shares worth $32M.
- Affinity Asset Advisors added most to Insmed in Q2 2025, an estimated $25.6M increase.
- Affinity Asset Advisors's biggest Q2 2025 reduction was Apogee Therapeutics, cutting an estimated $17.5M.
- Affinity Asset Advisors fully exited State Street SPDR S&P 500 ETF Trust in Q2 2025, selling an estimated $16.8M.
- Affinity Asset Advisors's ten largest holdings make up 47% of its $732M portfolio in Q2 2025.
- Affinity Asset Advisors opened 21 new positions and closed 28 in Q2 2025.
- Affinity Asset Advisors's portfolio value fell 30% quarter-over-quarter to $732M.
Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.